UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (212) 867-0700 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Commission file number: 001-35212 PIONEER POWER SOLUTIONS, INC ...

Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-07731 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 EMERSON RADIO CORP. (Exact name of registrant as specified in its charter) Delaware 22-3285224 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to _______________ Commission file number 001-41952 Telomir Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Florida 87-2606031 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 100 SE 2 St, Suite 200 #1009 Miami, Florida 331 ...

"We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems," stated Tivic CEO Jennifer Ernst. "To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit the ClearUP business by the end of this year," continued Ernst. "I look forward ...

Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission file number: 001-39126 CNS Pharmaceuticals, Inc. (Name of registrant as specified in its charter) (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) Delaware 45-3757789 (I.R.S. Employer Identification No.) 685 Route 202/206 N, Suite 301 Bridgewater, New Jersey 08807 (Address of principal executive offices including zip code) FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) ...

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2025 Delaware 13-3545623 State or other jurisdiction of Incor ...

[PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) Presents the unaudited condensed interim consolidated financial statements and management's discussion and analysis for the period ended June 30, 2025 [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements.) Presents unaudited condensed interim consolidated financial statements for Flexible Solutions International, Inc. as of June 30, 2025, and for the three and six-month periods then ended [Condensed Interim Consolidated Balance Sheets](index=5&type=section&id=%28a%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Balance%20Sheets%20at%20June%2030%2C%202025%20and%20December%2031%2C%202024.) Total assets slightly decreased to $58.2 million, while total liabilities decreased to $15.7 million, leading to increased stockholders' equity Consolidated Balance Sheet Summary (in USD) | Balance Sheet Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $31,092,253 | $34,575,857 | | **Total Assets** | $58,234,048 | $59,968,579 | | **Total Current Liabilities** | $9,151,454 | $11,861,667 | | **Total Liabilities** | $15,654,667 | $18,602,553 | | **Total Stockholders' Equity** | $42,579,381 | $41,366,026 | [Consolidated Statements of Operations (Three Months)](index=6&type=section&id=%28b%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20%28Loss%29%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024.) Q2 2025 sales increased to $11.4 million, driven by new R&D services revenue, resulting in higher net income and diluted EPS Q2 Financial Performance (in USD) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Total Sales | $11,367,132 | $10,528,739 | | Gross Profit | $5,385,266 | $3,939,095 | | Operating Income | $3,297,114 | $1,970,912 | | Net Income (attributable to FSI) | $2,028,912 | $1,289,796 | | Diluted EPS | $0.15 | $0.10 | - A new revenue stream from research and development services contributed **$2.5 million** in sales for Q2 2025, which was not present in Q2 2024[15](index=15&type=chunk) [Consolidated Statements of Operations (Six Months)](index=7&type=section&id=%28c%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025%20and%202024.) H1 2025 sales decreased to $18.8 million, but gross profit increased, with net income remaining stable at $1.75 million First Half Financial Performance (in USD) | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Total Sales | $18,840,824 | $19,753,611 | | Gross Profit | $7,336,830 | $6,759,462 | | Operating Income | $3,227,957 | $2,736,743 | | Net Income (attributable to FSI) | $1,751,178 | $1,747,022 | | Diluted EPS | $0.13 | $0.14 | [Consolidated Statements of Cash Flows](index=8&type=section&id=%28d%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Statements%20of%20Cash%20Flows%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025%20and%202024.) Cash from operations decreased to $4.7 million in H1 2025, with funds primarily used for capital expenditures, debt repayment, and dividends Cash Flow Summary for Six Months Ended June 30 (in USD) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash from Operating Activities | $4,738,637 | $5,309,855 | | Net cash from Investing Activities | ($1,331,042) | ($1,236,697) | | Net cash from Financing Activities | ($3,709,588) | ($2,633,885) | | **Net Change in Cash** | **($32,639)** | **$1,501,614** | [Consolidated Statements of Stockholders' Equity](index=9&type=section&id=%28e%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Statements%20of%20Stockholders%27%20Equity%20for%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202025%20and%202024.) Stockholders' equity increased to $42.6 million by June 30, 2025, driven by net income and stock option exercises, offset by dividends - Total stockholders' equity increased to **$42,579,381** at June 30, 2025, up from **$41,366,026** at December 31, 2024[18](index=18&type=chunk) - The company paid dividends of **$1,274,753** during the first six months of 2025[18](index=18&type=chunk) [Notes to Financial Statements](index=11&type=section&id=%28f%29%20Notes%20to%20Unaudited%20Condensed%20Interim%20Consolidated%20Financial%20Statements%20for%20the%20Period%20Ended%20June%2030%2C%202025.) Provides detailed explanations of accounting policies, financial figures, and segment reporting for the interim consolidated financial statements - The company's business involves manufacturing and marketing specialty chemicals for water evaporation control (HEATSAVR®, WATERSAVR®) and thermal polyaspartate biopolymers (TPAs) for industrial and agricultural applications[23](index=23&type=chunk) - Revenue from research and development services is recognized over time as contractual performance obligations are satisfied[29](index=29&type=chunk) - The company's three primary customers accounted for **47%** of sales in the first six months of 2025, down from **50%** in the same period of 2024, with a single customer for R&D services accounting for **13%** of total sales[31](index=31&type=chunk) [Management's Discussion and Analysis (MD&A)](index=23&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operation.) Management discusses financial results for Q2 and H1 2025, covering sales performance, expenses, liquidity, and capital resources - The company operates through two main divisions: Energy and water conservation products (EWCP) and Biodegradable polymers (BCPA), which also includes nitrogen conservation products and R&D services[77](index=77&type=chunk)[78](index=78&type=chunk)[79](index=79&type=chunk) - Key factors expected to affect future results include crude oil prices, oil and gas industry activity, drought conditions for agricultural sales, and potential tariffs on materials from China[86](index=86&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) Product sales decreased in H1 2025, offset by new R&D services revenue, leading to increased gross profit percentage and mixed operating expenses Key Changes in Operations (Six Months Ended June 30, 2025 vs 2024) | Item | Change | Reason | | :--- | :--- | :--- | | EWCP & BCPA Product Sales | Decrease | Decreased customer orders | | R&D Services Sales | Increase | Successful project completed in 2025 | | Gross Profit % | Increase | Higher margin on R&D sales | | Consulting Expense | Decrease | Decreased reliance on consultants | | Professional Fees | Increase | Higher accounting and audit fees due to growth | | Interest Expense | Increase | Increased debt levels | - Customer concentration remains significant, with three customers accounting for **47%** of product sales in the first half of 2025, and a new R&D services customer (Company E) becoming a major revenue source[82](index=82&type=chunk)[83](index=83&type=chunk) [Capital Resources and Liquidity](index=26&type=section&id=Capital%20Resources%20and%20Liquidity) The company maintains strong liquidity with $21.9 million in working capital, primarily funding operations, capital expenditures, debt, and dividends Sources and Uses of Cash (Six Months Ended June 30) | Item (in USD) | 2025 | 2024 | | :--- | :--- | :--- | | Cash from operating activities | 4,738,637 | 5,309,855 | | Purchase of property and equipment | (1,331,042) | (1,663,697) | | Repayment of debt (net) | (2,576,556) | (1,039,438) | | Dividends paid | (1,274,753) | (1,255,053) | - Working capital was **$21,940,799** as of June 30, 2025, compared to **$22,714,190** at December 31, 2024[85](index=85&type=chunk) - The company does not anticipate any significant capital requirements for the twelve months ending June 30, 2026[87](index=87&type=chunk) [Controls and Procedures](index=28&type=section&id=Item%204.%20Controls%20and%20Procedures.) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes in internal control - Based on an evaluation as of June 30, 2025, the Principal Executive and Financial Officer concluded that the company's disclosure controls and procedures are effective[89](index=89&type=chunk) - No changes occurred in the company's internal control over financial reporting during the three months ended June 30, 2025, that materially affected, or are reasonably likely to materially affect, these controls[90](index=90&type=chunk) [PART II. OTHER INFORMATION AND EXHIBITS](index=28&type=section&id=PART%20II.%20OTHER%20INFORMATION%20AND%20EXHIBITS) Presents other required information and a list of exhibits filed as part of the Form 10-Q report [Other Information](index=28&type=section&id=Item%205.%20Other%20Information.) No directors or officers adopted or terminated Rule 10b5-1 trading arrangements during the quarter ended June 30, 2025 - No directors or officers adopted or terminated a Rule 10b5-1 trading arrangement during the quarter ended June 30, 2025[92](index=92&type=chunk) [Exhibits](index=28&type=section&id=Item%206.%20Exhibits.) Lists certifications by executive and financial officers, along with Inline XBRL data files, as part of the Form 10-Q report List of Exhibits | Number | Description | | :--- | :--- | | 31.1 | Certification of Principal Executive Officer (Sarbanes-Oxley Act §302) | | 31.2 | Certification of Principal Financial Officer (Sarbanes-Oxley Act §302) | | 32.1 | Certification of Principal Executive and Financial Officer (Sarbanes-Oxley Act §906) | | 101 | Inline XBRL Documents | | 104 | Cover Page Interactive Data File |

Exhibit 99.1 Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued Enrollment Multiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting Contraception Four Commercially Available Solutions for Women on the Horizon Conference Call Toda ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-42139 Actuate Therapeutics, Inc. (Exact name of registrant as specified in its charter) De ...